Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Enanta Pharmaceuticals from “hold” to “sell,” despite the broader analyst consensus remaining “Moderate Buy” with a $19.50 price target.
• Enanta’s latest quarterly results missed expectations, reporting a loss of $0.67 per share versus the $0.51 consensus estimate and revenue of $14.36 million versus $16.76 million expected.
• Shares opened at $13.47, while the company reported a negative net margin of 96.89% and negative return on equity of 61.84%; institutional investors own nearly 95% of the stock.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

A number of other analysts also recently issued reports on ENTA. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.50.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $13.47 on Friday. Enanta Pharmaceuticals has a 52-week low of $7.05 and a 52-week high of $17.15. The company has a market capitalization of $392.25 million, a PE ratio of -5.59 and a beta of 0.98. The business's fifty day moving average is $13.43 and its 200 day moving average is $13.46.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The business had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -1.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $32,000. Seven Fleet Capital Management LP purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth about $36,000. Legal & General Group Plc bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at about $41,000. Strs Ohio bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock valued at $57,000 after buying an additional 2,758 shares in the last quarter. Institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source